Skip to content

York conference explores new developments in cancer treatment

Posted on 30 April 2013

The University of York is the venue for an international conference next month on the pathogenesis and treatment of lymphomas, the most common type of cancers of the blood in the developed world.

Roche and C2D2 logos

The conference, B-cell malignancies: the impact of biomarkers on treatment decisions, will be held in the National Science Learning Centre on the University’s Heslington campus on 10 May, 2013.

Hosted by the Epidemiology and Cancer Statistics Group (ECSG), which is based in the University’s Department of Health Sciences, the one-day event is organised by the Haematological Malignancy Research Network (www.hmrn.org) of which ECSG is an integral partner. It is also held in association with the Lunenburg Lymphoma Biomarker Consortium, an international initiative dedicated to identifying and evaluating biomarkers (biological characteristics used to diagnose disease and/or predict treatment response) that will improve lymphoma detection and treatment.

The conference brings together distinguished research scientists from leading institutions around the world including: the British Columbia Cancer Agency, Universität des Saarlandes, Barts Cancer Institute and the Wellcome Trust Sanger Institute, among others. The invited speakers are all internationally recognized experts in their fields, which range from bioinformatics and prognostic modelling through to haematopathology, nuclear medicine and medical oncology.

This event illustrates the diverse collaborations University of York researchers are forging and will provide a unique opportunity for young researchers to hear from some of the most influential scientists in the field

Professor Eve Roman

Presentations will focus on various aspects of current lymphoma research, such as: the management of patients though novel treatments; analysis of gene expression profiles in clinical samples and their relationship with changing molecular profiles; functional genomics and systems biology; the delivery of more robust clinical trials; and the application of new imaging techniques to lymphoma management. 

The conference will be attended by academics, researchers, students, pharmaceutical industry workers and NHS practitioners, including consultants and clinical nurse specialists.

Professor Eve Roman, Director of the Epidemiology and Cancer Statistics Group at York, said: “The conference will offer a challenging multi-disciplinary research perspective on ways to tackle one of the most important health issues facing the developed world. This event illustrates the diverse collaborations University of York researchers are forging and will provide a unique opportunity for young researchers to hear from some of the most influential scientists in the field.”

The event has been supported by the Centre for Chronic Diseases and Disorders (C2D2) and Roche.

Notes to editors:

  • More about the conference at www.biomarkerconf.co.uk
  • More about the University of York’s Epidemiology and Cancer Statistics Group at www.york.ac.uk/healthsciences/research/cancer-cardio/ecsg/
  • The Haematological Malignancy Research Network (HMRN) is a collaborative venture between NHS practitioners, the Haematological Malignancy Diagnostic Service (which diagnoses all haematological malignancies in the area) and researchers at the Epidemiology and Genetics Unit, University of York (who manage data collection and analysis). As part of the registry, routine demographic, prognostic, treatment and outcome data are collected on all patients, as well as place and cause of death. For further information, visit www.HMRN.org
  • The University of York is committed to research into alleviating the world-wide burden of chronic diseases and disorders. With the support of the Wellcome Trust, the University has established the Centre for Chronic Diseases and Disorders (C2D2 - www.york.ac.uk/c2d2/) to coordinate and maximise the impact of this key interdisciplinary field of research.

Contact details

David Garner
Senior Press Officer

Tel: +44 (0)1904 322153

Keep up to date

 Subscribe to news feeds

 Follow us on Twitter